No spam - just the good stuff
Subscribe to our newsletter
First Name
(Required)
Email Address
(Required)
Hidden
Contact Source
News
Investor Portal
Lifestyle
Videos
Search for:
Search
More
Contact
Features
News
Home
Biotech
Investment
Diagnostics
Agetech
Supplements
Innovation
AI/Digital
Economy
Biotech
Merck bolsters neurodegeneration program with Caraway acquisition
Biotech
Beyond Yamanaka: Mogrify demystifies cellular reprogramming
Biotech
Loyal gets promising FDA feedback on lifespan extension drug for dogs
Company founder says FDA has formally accepted that a drug can be developed and approved to extend lifespan.
Biotech
Quotient emerges with $50m to harness genetic variation at the cellular level
Biotech
Vivodyne lands $38m to predict drug effects using lab-grown organs
Biotech
Improving healthspan and longevity can be just like riding a bike
Biotech
Over 30? Time to get proactive about health, longevity and disease prevention
Biotech
GenSight to receive €4 million after completing second successful GMP batch of gene therapy
Biotech
Will proteomics provide the answers to aging and longevity?
Biotech
VectorY lands $138m to target neurodegeneration with vectorized antibodies
Biotech
OrsoBio roars with $60m to treat metabolic disorders
Biotech
Xenotransplantation comes of age
Biotech
Forward Therapeutics lands $50m to target chronic inflammation
Biotech
T3D’s Phase 2 Alzheimer’s trial yields promising results
Biotech
Mogling Bio secures additional funding to advance rejuvenation tech
Biotech
Can restoring elastin with existing drugs improve longevity?
Biotech
BioAge announces Phase 2 trial of obesity drug
Biotech
Will Turn Bio be the first longevity company to take cell rejuvenation to the clinic?
Biotech
LyGenesis bags $19m to complete key clinical trial and advance cell therapy pipeline
Biotech
Endogena gets FDA green light for AMD trial
Biotech
ADDF backs Curasen with $5.8m to advance Alzheimer’s program
Biotech
Amplifier doses first patients in trial and closes new financing
Biotech
AbbVie targets Parkinson’s with $110m Mitokinin acquisition
Biotech
AstronauTx blasts off with $61m for Alzheimer’s drug development
Biotech
VitaDAO community launches its first biotech company
Biotech
Beyond the secretome: targeting age-related immune decline
Biotech
Gameto inks stem cell deal with Reprocell for female fertility program
Biotech
‘We are so close to the future we want’
Biotech
ExcepGen emerges from stealth, targets genetic medicine revolution
Biotech
Rejuvenate Biomed announces positive results from sarcopenia clinical trial
Biotech
Mogrify boosts Series A to $46m to advance cellular reprogramming therapies
Biotech
Standing at the precipice of a biotech renaissance – the confluence of AI and SynBio
Biotech
Load More